CONSORTIUM - A Double-Blind Placebo-Controlled Phase 2 Study of VE303 for Prevention of Recurrent Clostridium (Clostridioides) Difficile Infection
Phase of Trial: Phase II
Latest Information Update: 14 Jan 2020
Price : $35 *
At a glance
- Drugs VE 303 (Primary)
- Indications Clostridium difficile infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms CONSORTIUM
- Sponsors Vedanta Biosciences
- 05 Dec 2019 Planned End Date changed from 1 Mar 2020 to 1 May 2020.
- 05 Dec 2019 Planned primary completion date changed from 1 Nov 2019 to 1 Mar 2020.
- 23 Sep 2019 According to a Vedanta Biosciences media release, the funding from recent series C-2 financing ($16.6 million) will support this trial.